Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 65, Issue 4, Pages 365-375Publisher
SPRINGER
DOI: 10.1007/s00228-008-0584-5
Keywords
Warfarin; CYP2C9; Pharmacogenetics; Genetic polymorphism; Meta-analysis; Drug interactions
Categories
Funding
- Swedish Foundation for Strategic Research
- Swedish Science Council [04496]
- Swedish Drugs and Therapeutics Committee of Southwest Stockholm
Ask authors/readers for more resources
To quantify the influence of common cytochrome P450 2C9 (CYP2C9) polymorphisms on warfarin dose requirements. A systematic review and a meta-analysis, calculating the warfarin dose reduction associated with the five most common variant CYP2C9 genotypes. Thirty-nine studies (7,907 patients) were included in the meta-analysis. Compared to the CYP2C9*1/*1 genotype, the CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, and CYP2C9*3/*3 required warfarin doses that were 19.6 (95% confidence interval 17.4, 21.9), 33.7 (29.4, 38.1), 36.0 (29.9, 42.0), 56.7 (49.1, 64.3), and 78.1% (72.0, 84.3) lower, respectively. The impact of CYP2C9 genotype tended to be larger in patients without interacting drugs. Previous studies have rarely been powered to determine the quantitative influence of specific CYP2C9 genotypes on warfarin dose requirements. The results from our pooled analysis are likely to be the most accurate to date and the methodology could serve as a model for future pharmacogenetic meta-analyses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available